July 2019

Biopharmaceutical Company Chimerix, Inc. Acquires Rights to Promising Leukemia Treatment

North America - United States | North America | United States - North Carolina

Chimerix, Inc., a biopharmaceutical company based in Durham, North Carolina, entered into a License and Development Agreement with Cantex Pharmaceuticals pursuant to which Chimerix acquired exclusive worldwide rights to develop and commercialize a drug candidate known as CX-01, which targets multiple proteins involved in cancer cell resistance to chemotherapy. Chimerix intends to initiate, in mid-2020, a Phase 3 registrational trial of CX-01 for the treatment of acute myeloid leukemia in the first-line setting. In consideration for the license rights, Cantex received an upfront cash payment of $30 million plus 10 million shares of Chimerix common stock and is eligible to receive milestone payments of up to $587.5 million plus tiered royalties based on Chimerix’s future sales of CX-01.

Faegre Baker Daniels represented Chimerix in the deal.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.